Histone deacetylase inhibitors modulate hormesis in leukemic cells with mutant FMS-like tyrosine kinase-3

Leukemia. 2023 Nov;37(11):2319-2323. doi: 10.1038/s41375-023-02036-2. Epub 2023 Sep 21.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Proliferation
  • Histone Deacetylase Inhibitors* / pharmacology
  • Hormesis
  • Humans
  • Vascular Endothelial Growth Factor Receptor-1*
  • fms-Like Tyrosine Kinase 3

Substances

  • Histone Deacetylase Inhibitors
  • Vascular Endothelial Growth Factor Receptor-1
  • fms-Like Tyrosine Kinase 3